Emerging immunotherapy for HCC

Emerging immunotherapy for HCC: A guide for hepatologists

HCC is one of the most common cancers worldwide, and the third leading cause of cancer-related death globally. HCC comprises nearly 90% of all cases of ...

Emerging immunotherapy for HCC: A guide for hepatologists

ICI therapies have demonstrated robust efficacy in a subset of patients across a variety of malignancies including HCC. The combination of the anti‐PDL1 ...

Immunotherapy for hepatocellular carcinoma: Current status and ...

In current years, cancer immunotherapy has made significant progress, opening up new treatment options for HCC. HCC, on the other hand, has a variety of ...

Immunotherapy of hepatocellular carcinoma: recent progress and ...

Camrelizumab plus FOLFOX or GEMOX chemotherapy is well tolerated and may provide a new option for patients with advanced HCC. 2.3 Combination with anti- ...

Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)

In 2020, a nivolumab plus ipilimumab combination was approved for the treatment of patients with advanced HCC who were previously treated with ...

A multidisciplinary approach with immunotherapies for advanced ...

Immune checkpoint inhibitors (ICIs) have emerged as promising treatments for HCC. Notably, nivolumab and pembrolizumab, anti-programmed cell ...

Advances in immunotherapy for hepatocellular carcinoma - Nature

The FDA, EMA and other regulatory agencies worldwide have approved the atezolizumab plus bevacizumab combination for first-line therapy in HCC.

Immune checkpoint inhibitors in hepatocellular carcinoma: emerging ...

In this Viewpoint, we discuss the major gaps in knowledge around the role of ICI-based therapies in patients with Child-Pugh class B.

New techniques: a roadmap for the development of HCC ... - Frontiers

The investigation of the tumour microenvironment and immunotherapy in patients with HCC has been ongoing for several years. However, the ...

Emerging immunotherapy for HCC: A guide for hepatologists - aasld

The tumor immune microenvironment of HCC has significant immunosuppressive elements that may affect response to immunotherapy. Major unmet ...

The Era of Immunotherapy in Hepatocellular Carcinoma - MDPI

The immune microenvironment of HCC plays a crucial role in tumor development and drug responses. However, due to the complexity of immune ...

Updates on Systemic Therapy for Hepatocellular Carcinoma

Adjuvant therapies face hurdles, but noteworthy advances include IMbrave050 setting a new standard with atezolizumab/bevacizumab. Locoregional ...

Combination immunotherapy for hepatocellular carcinoma

Immunotherapy combinations tested in phase III trials include ICIs and bevacizumab, ICIs and tyrosine kinase inhibitors, and the combination of ...

Emerging immunotherapy biomarkers for predicting systemic ...

ASCO GI 2024 | Emerging immunotherapy biomarkers for predicting systemic therapy in HCC ... Mark Yarchoan, MD, Johns Hopkins University, Baltimore ...

Immune checkpoint inhibitors in hepatocellular carcinoma

Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice ; Matthias Pinter · MD PhD ; Bernhard Scheiner · MD ; David J ...

Emerging data on immune checkpoint inhibitors in the neoadjuvant ...

The IMbrave150 and HIMALAYA trials established immunotherapy as the first-line treatment for patients with advanced HCC. Therefore, there has ...

Immunotherapy for hepatocellular carcinoma - JHEP Reports

The approval of immunotherapy-based therapies in HCC has significantly altered the prognosis for patients with advanced HCC and become the new benchmark for ...

Immunotherapy for hepatocellular carcinoma: Recent advances and ...

However, due to the small rate of survival benefit and intolerance associated with TKIs, there is an urgent need for new therapeutic strategies. From this ...

Emerging role of molecular diagnosis and personalized therapy for ...

Curative treatments, such as surgical resection, liver transplantation, and local ablative therapies, are reserved for early-stage HCC patients [5]. For ...

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular ...

Several cancer immunotherapies that target the PD-L1–PD-1 pathway (i.e., checkpoint inhibitors) are currently being evaluated in patients with ...